McKesson Corporation
Every calculator, already run for MCK
Open the full toolkit →You have the numbers on MCK. Get the argument.
A written report on which of these readings actually decide the outcome for McKesson Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
18 analysts covering MCKAnalyst Price Target Disagreement for McKesson Corporation
Wall Street's bull case implies +22% from the current price; the bear case implies -3%. Analysts are relatively aligned on MCK's range.
Ownership & short interest
Insider Trading Activity for MCK
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical s…
MCK — frequently asked
Is MCK a buy right now?
Wall Street's consensus rating on McKesson Corporation is Buy across 18 analysts, with a mean price target of $980.73 (+12% vs. the current $874.65). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is MCK overvalued?
MCK trades at 23.5x trailing earnings, against a DCF fair value of $2266 per share. The current price implies -5% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is MCK's next earnings date?
McKesson Corporation is next scheduled to report earnings around Nov 4, 2026. A full MCK research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for McKesson Corporation?
Analysts covering McKesson Corporation (MCK) range from a bear-case target of $845.00 to a bull-case high of $1,065.00, with a mean consensus target of $980.73 across 15 analysts. The spread of $220.00 (25% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare McKesson Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For McKesson Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MCK research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on McKesson Corporation, in minutes. 3 free reports included with every account — no credit card required.